JP2008520186A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520186A5 JP2008520186A5 JP2007533961A JP2007533961A JP2008520186A5 JP 2008520186 A5 JP2008520186 A5 JP 2008520186A5 JP 2007533961 A JP2007533961 A JP 2007533961A JP 2007533961 A JP2007533961 A JP 2007533961A JP 2008520186 A5 JP2008520186 A5 JP 2008520186A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- derivative
- fragment
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 25
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 25
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 102100022810 Potassium voltage-gated channel subfamily H member 1 Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 7
- 230000003463 hyperproliferative effect Effects 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108050000074 Potassium voltage-gated channel subfamily H member 1 Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 102100025071 Potassium voltage-gated channel subfamily H member 5 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04023489 | 2004-10-01 | ||
| PCT/EP2005/010671 WO2006037604A1 (en) | 2004-10-01 | 2005-10-04 | Novel antibodies directed to the mammalian eag1 ion channel protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520186A JP2008520186A (ja) | 2008-06-19 |
| JP2008520186A5 true JP2008520186A5 (enExample) | 2009-05-28 |
Family
ID=34926818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007533961A Pending JP2008520186A (ja) | 2004-10-01 | 2005-10-04 | 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7910100B2 (enExample) |
| EP (1) | EP1805222B1 (enExample) |
| JP (1) | JP2008520186A (enExample) |
| AT (1) | ATE497508T1 (enExample) |
| AU (1) | AU2005291486A1 (enExample) |
| CA (1) | CA2582683A1 (enExample) |
| DE (1) | DE602005026219D1 (enExample) |
| WO (1) | WO2006037604A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| TWI551607B (zh) | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| AU2007288118A1 (en) * | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Anti-C5aR antibodies with improved properties |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US7858752B2 (en) | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| JP5142265B2 (ja) * | 2007-05-28 | 2013-02-13 | 独立行政法人産業技術総合研究所 | 抗モータリン抗体のパラトープ及びエピトープ |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| EP2171449A2 (en) * | 2007-06-20 | 2010-04-07 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| CA2701793C (en) | 2007-10-05 | 2017-04-25 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| US20100291108A1 (en) * | 2007-10-16 | 2010-11-18 | Arie Abo | Antibodies to irem-1 |
| EP2220121B1 (en) | 2007-11-12 | 2015-08-19 | U3 Pharma GmbH | Axl antibodies |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CN102076355B (zh) * | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| SG191639A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009256246B2 (en) * | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| AU2009268585C1 (en) * | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| AU2009282806B2 (en) * | 2008-08-20 | 2014-10-30 | New York Blood Center, Inc. | High throughput system for CFU assay by the use of high resolution digital imaging, differential staining and automated laboratory system |
| US8512677B2 (en) * | 2009-04-27 | 2013-08-20 | Case Western Reserve University | Pyro-glutamate Aβ targeting agents |
| KR20120035145A (ko) | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
| EP2270053A1 (en) * | 2009-05-11 | 2011-01-05 | U3 Pharma GmbH | Humanized AXL antibodies |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| TW201119673A (en) * | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CA2772613C (en) * | 2009-09-03 | 2020-03-10 | Schering Corporation | Anti-gitr antibodies |
| CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
| UY32948A (es) * | 2009-10-15 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2011063523A1 (en) * | 2009-11-24 | 2011-06-03 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| AR083705A1 (es) * | 2010-11-04 | 2013-03-13 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2013102042A2 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
| CA2862739A1 (en) | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| EP2831813B1 (en) | 2012-03-28 | 2019-11-06 | University of Houston System | Methods and software for screening and diagnosing skin lesions and plant diseases |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| HK1212359A1 (en) | 2012-11-01 | 2016-06-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| JP6674888B2 (ja) * | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| JPWO2014175444A1 (ja) * | 2013-04-26 | 2017-02-23 | 千葉県 | 抗ｎｌｒｒ１抗体 |
| BR112016013641A2 (pt) | 2013-12-12 | 2017-08-08 | Umc Utrecht Holding Bv | Moléculas tipo imunoglobulina direcionadas contra fibronectina-eda |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| WO2016199097A1 (en) * | 2015-06-10 | 2016-12-15 | National Research Council Of Canada | Carbonic anhydrase ix-specific antibodies and uses thereof |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| CN109219615B (zh) | 2016-05-02 | 2022-12-09 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| PL3452507T3 (pl) | 2016-05-02 | 2023-01-09 | Prothena Biosciences Limited | Immunoterapia tau |
| EP3452509A1 (en) | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| WO2017218691A1 (en) * | 2016-06-16 | 2017-12-21 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd81 |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| AU2020231366A1 (en) | 2019-03-03 | 2021-08-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN110616192B (zh) * | 2019-08-09 | 2021-11-09 | 无锡傲锐东源生物科技有限公司 | 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用 |
| JP7697695B2 (ja) | 2020-01-21 | 2025-06-24 | タボテック バイオテクノロジー（チャンスー）カンパニー リミテッド | ＩＬ－１β受容体シグナル伝達に干渉する剤 |
| EP4161565A4 (en) * | 2020-06-05 | 2024-07-24 | The Johns Hopkins University | Humanized antibodies directed against kcnk9 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5750172A (en) * | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ATE193301T1 (de) * | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6203822B1 (en) | 1996-09-03 | 2001-03-20 | University Of Iowa Research Foundation | Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection |
| JP3998419B2 (ja) | 1998-04-03 | 2007-10-24 | 中外製薬株式会社 | ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法 |
| DK1073738T3 (da) * | 1998-04-21 | 2005-01-24 | Max Planck Gesellschaft | Human K+-ionkanal og terapeutiske applikationer deraf |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US20040254108A1 (en) * | 2003-06-13 | 2004-12-16 | Jing Ma | Preparation and application of anti-tumor bifunctional fusion proteins |
-
2005
- 2005-10-04 US US11/664,345 patent/US7910100B2/en not_active Expired - Fee Related
- 2005-10-04 EP EP05797335A patent/EP1805222B1/en not_active Expired - Lifetime
- 2005-10-04 JP JP2007533961A patent/JP2008520186A/ja active Pending
- 2005-10-04 WO PCT/EP2005/010671 patent/WO2006037604A1/en not_active Ceased
- 2005-10-04 AT AT05797335T patent/ATE497508T1/de not_active IP Right Cessation
- 2005-10-04 AU AU2005291486A patent/AU2005291486A1/en not_active Abandoned
- 2005-10-04 CA CA002582683A patent/CA2582683A1/en not_active Abandoned
- 2005-10-04 DE DE602005026219T patent/DE602005026219D1/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520186A5 (enExample) | ||
| JP2020515235A5 (enExample) | ||
| JP2020503870A5 (enExample) | ||
| IL256870B2 (en) | Constructs for bispecific antibodies that bind to CD70 and CD3 and uses thereof | |
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| IL256871B2 (en) | Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof | |
| RU2011124751A (ru) | Антитело против смет | |
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
| JP2012523848A5 (enExample) | ||
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| JP2013523166A5 (enExample) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| JP2012525432A5 (enExample) | ||
| RU2011115559A (ru) | Антитела к cxcr4 и их применение для лечения рака | |
| JP2009518039A5 (enExample) | ||
| JP2008529489A5 (enExample) | ||
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| JP2011505810A5 (enExample) | ||
| HRP20140502T1 (hr) | Humanizirana anti-cxcr4 antitijela za lijeäśenje karcinoma | |
| HRP20171274T1 (hr) | U potpunosti ljudska antitijela specifična za cadm1 | |
| JP2013520174A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| JP2021526820A (ja) | 癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体 | |
| RU2019143101A (ru) | Новое анти-с-мет антитело и его применение |